cholera

Local media reported Monday that Mumbai-based TechInvention has struck an import deal with EuBiologics to market the South Korean company’s oral cholera vaccine (OCV) in India.

Business Standard quoted TechInvention CEO Syed Ahmed as saying the move fills a market gap resulting from Sanofi’s OCV production pause at its Shantha subsidiary. TechInvention is targeting a price range for Euvichol-Plus of $8-$10 per single dose in India’s private market, according to the article. The company…

A novel, temperature-stable, cholera toxin B (CTB) subunit vaccine candidate made of powdered, genetically modified Japanese short-grain rice produced no obvious side effects and generated a “good immune response” in a Phase 1 trial, the University of Tokyo announced last week.

Volunteers who responded to MucoRice-CTB showed increased CTB-specific antibodies in a “gut microbiota-dependent manner,” and those receiving a higher dose were more likely to have CTB-specific antibodies,…

Denmark’s Bavarian Nordic and France’s Valneva announced last week that they have struck a deal to market and distribute each other’s vaccine products.

Valneva will assume the rights to Bavarian Nordic’s two travel vaccines for rabies and tick-borne encephalitis (acquired from GSK last year) in “selected European countries and Canada” beginning in the second half of 2020, and take over markets in the United States, Germany and Switzerland later this year.

In exchange, Bavarian…

Seoul-based International Vaccine Institute (IVI) announced last week that the Gates Foundation is giving the nonprofit $1.4 million to develop international standards and reference reagents for oral cholera vaccine manufacturers—upping the foundation’s investment in IVI’s cholera program to $24.4 million to date.

In other news, IVI also announced this week that it has signed a five-year, $5.24 million partnership with the Swedish International Development Cooperation Agency to support…

Mentions:

The Seoul-based International Vaccine Institute (IVI) announced this week that the Gates Foundation is giving it $4.5 million to explore modifications and optimize a single manufacturing process for oral cholera vaccine (OCV) produced by neighboring South Korean manufacturer EuBiologics—with the goal of increasing production capacity and lowering costs.

According to the IVI press release, to date, the Gates Foundation has invested $23 million in the institute’s program to develop a low…

San Francisco–based Jaguar Health announced today that it has completed pre-clinical studies and will file an Investigational New Drug (IND) application for its cholera and acute diarrhea drug, lechlemer—derived from the Croton lechleri tree.

According to the press release, Jaguar plans to conduct clinical studies at the International Centre for Diarrhoeal Disease Research in Bangladesh and will target “resource-constrained countries where cost of goods is a factor.”

Korea’s Research Investment for Global Health Technology (RIGHT) Fund announced its first four recipients of $5.8 million in grants last week at its 2019 investment forum.

EuBiologics (with Seoul’s International Vaccine Institute, Massachusetts General Hospital and Harvard Medical School) won support for its preclinical cholera conjugate vaccine.

SK Biotek (with the Medicines for Malaria Venture) will get funding for continuous process development and scale-up of new malaria…

India’s Hilleman Laboratories announced today that it will work with Bharat Biotech International Limited (BBIL) to further develop, manufacture and commercialize its oral cholera vaccine (OCV) candidate.

Hyderabad-based BBIL will scale Hillchol’s manufacturing process to commercial stage and establish product specifications required for WHO pre-qualification, a Hilleman press release said.

Researchers from the U.S. FDA published findings in PLOS last week showing the FDA’s Priority Review Voucher incentive has stimulated drug development for tropical diseases.

Using data from Citeline’s PharmaProjects database, the researchers found a large spike in development in 2009 (when the first PRV was awarded) and a second large increase in initial development in 2016 (after multiple PRVs sold for up to $350 million). However, development has focused mainly on dengue, malaria…

Maryland-based Emergent Bio announced last week that it is buying Californian company PaxVax from Cerberus Capital Management for $270 million.

Emergent gains the only U.S. FDA–approved cholera and typhoid vaccines, plus a Phase 2 chikungunya vaccine candidate and a U.S. military contract to develop an adenovirus 4/7 vaccine. Emergent also wins cGMP biologics facilities in Europe, a company press release said.

Emergent expects the transaction to close in the fourth quarter of…